POSEIDON Trial

Episode
133
Soundcloud
Share

Dr. Narjust Florez discusses the POSEIDON trial with guest Dr. Tejas Patil, assistant professor at Thoracic Oncology Research Initiative, University of Colorado Cancer Center. This Phase III study led to the recent FDA approval of Tremelimumab in combination with Durvalumab and chemotherapy as first-line treatment in patients with metastatic non small-cell lung cancer (NSCLC). 

Guest
Narjust Florez Headshot 2022
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Tejas Patil
Tejas Patil

MD

Assistant Professor
University of Colorado Cancer Center

Other Podcast

Lung Cancer in Brazil
Episode
141
Patient Advocacy Groups Podcast
Episode
140
Radon Podcast
Episode
139
FDA Approval: Adagrasib
Episode
138